8 June 2015: advertising of Prednisolone Dompé
Published 20 July 2015
© Crown copyright 2015
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-june-2015/8-june-2015-advertising-of-prednisolone-dompe
Amdipharm Mercury Company Ltd complained about an email advert for Prednisolone Dompé 1mg/ml oral solution produced by LogixX Pharma sent to subscribers of GP Online in April 2015. The complainant alleged that the advert was misleading because it stated that the product was:
- “safe”
- a comparable, generic oral solution, alternative to the prednisolone 5mg soluble tablets but the product was not indicated for doses above 30mg
- “36% cheaper than prescribing prednisolone 5mg soluble tablets (mg/mg)” but this could not be substantiated for all doses
MHRA upheld the complaint. LogixX Pharma promptly withdrew the advert and related material and made changes to correct the information.